Combining chemotherapy with a new treatment method for pancreatic cancer
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
This study is looking at how well combining regular chemotherapy with a special treatment called endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) works for people with pancreatic cancer, hoping to boost their immune response and improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10846817 on NIH RePORTER |
What this research studies
This research investigates the safety and effectiveness of combining standard chemotherapy with endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for patients with pancreatic ductal adenocarcinoma (PDAC). The approach aims to address the challenges posed by the tumor's resistant nature and its complex microenvironment. By using EUS-RFA, the study seeks to improve the immune response against the cancer and potentially enhance the overall treatment outcomes. Patients will be closely monitored to assess the impact of this combined therapy on tumor progression and survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with resectable pancreatic ductal adenocarcinoma who are eligible for chemotherapy.
Not a fit: Patients with advanced or metastatic pancreatic cancer may not benefit from this research as it focuses on those with resectable tumors.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and better treatment options for patients with pancreatic cancer.
How similar studies have performed: Previous studies have shown promising results with similar approaches, indicating potential for significant advancements in treating pancreatic cancer.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Thosani, Nirav — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Thosani, Nirav
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.